Achieving inactive disease in enthesitis-related arthritis with secukinumab following TNF-inhibitor failure-Reference-Cited by-同舟云学术

Achieving inactive disease in enthesitis-related arthritis with secukinumab following TNF-inhibitor failure

Published:2023-12-07 Issue: Volume: Page:
ISSN:1462-0324
Container-title:Rheumatology
language:en
Short-container-title:

Author:

Papailiou Stayroula¹,Onoufriou Margarita²,Mentesidou Lida³^ORCID,Syggelou Angeliki¹,Tsolia Maria N¹,Maritsi Despoina N¹²

Affiliation:

1. 2nd Department of Pediatrics, ‘Panagiotis and Aglaia Kiriakou’ Children’s Hospital, National and Kapodistrian University of Athens , Athens, Greece

2. Department of Pediatrics, ‘Archbishop Makarios III’ Children’s Hospital , Leucosia, Cyprus

3. 1st Department of Pediatrics, ‘Panagiotis and Aglaia Kiriakou’ Children’s Hospital , Athens, Greece

Publisher

Oxford University Press (OUP)

Subject

Pharmacology (medical),Rheumatology

Link

https://academic.oup.com/rheumatology/advance-article-pdf/doi/10.1093/rheumatology/kead656/54753048/kead656.pdf

Reference8 articles.

1. Enthesitis-related juvenile idiopathic arthritis;Rosenthal;Pediatr Rev,2019

2. Enthesitis-related arthritis;Aggarwal;Clin Rheumatol,2015

3. Secukinumab provides sustained improvements in the signs and symptoms of active ankylosing spondylitis with high retention rate: 3-year results from the phase III trial, MEASURE 2;Marzo-Ortega;RMD Open,2017

4. Secukinumab 150/300 mg provides sustained improvements in the signs and symptoms of active ankylosing spondylitis: 3-year results from the phase 3 MEASURE 3 study;Pavelka;ACR Open Rheumatol,2020

5. Use of secukinumab in a pediatric patient leads to significant improvement in nail psoriasis and psoriatic arthritis;Wells;Pediatr Dermatol,2019

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Comment on: Achieving inactive disease in enthesitis-related arthritis with secukinumab following TNF-inhibitor failure;Rheumatology;2024-03-09